Relay Therapeutics (RLAY) Expected to Announce Quarterly Earnings on Monday

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 5th. Analysts expect Relay Therapeutics to post earnings of ($0.51) per share and revenue of $0.01 million for the quarter.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Stock Down 4.9 %

Shares of RLAY traded down $0.16 during mid-day trading on Tuesday, hitting $3.10. 1,540,862 shares of the company's stock traded hands, compared to its average volume of 1,986,443. Relay Therapeutics has a 1 year low of $1.78 and a 1 year high of $10.72. The firm has a market capitalization of $525.52 million, a P/E ratio of -1.19 and a beta of 1.70. The business's 50-day moving average price is $2.98 and its 200-day moving average price is $4.24.

Insider Transactions at Relay Therapeutics

In related news, CEO Sanjiv Patel sold 61,422 shares of the stock in a transaction dated Wednesday, April 23rd. The shares were sold at an average price of $2.97, for a total transaction of $182,423.34. Following the sale, the chief executive officer now directly owns 821,667 shares of the company's stock, valued at approximately $2,440,350.99. This represents a 6.96 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas Catinazzo sold 20,791 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $4.42, for a total transaction of $91,896.22. Following the sale, the chief financial officer now directly owns 379,431 shares in the company, valued at $1,677,085.02. This trade represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 320,131 shares of company stock valued at $1,183,624 in the last three months. 4.32% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wells Fargo & Company assumed coverage on Relay Therapeutics in a research note on Thursday, April 17th. They set an "equal weight" rating and a $4.00 target price on the stock. Stifel Nicolaus dropped their price target on Relay Therapeutics from $27.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. The Goldman Sachs Group decreased their price objective on Relay Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Finally, HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Relay Therapeutics in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $18.36.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.